Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1586

Shown on this page

Current sort

Live official records

Conditions: Damaged Chondral or Osteochondral Area
Interventions: Hyalex Knee Cartilage System; Device
Lead sponsor: Hyalex Orthopaedics, Inc.; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: La Mesa, California • New Orleans, Louisiana • New York, New York + 2 more

Conditions: Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 16
States / cities: Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 26
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 22 more

Conditions: Melanoma
Interventions: fianlimab, cemiplimab, relatlimab+nivolumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 106
States / cities: Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Duarte, California • Irvine, California • Sacramento, California + 6 more

Conditions: Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 412
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more

Conditions: Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: Naresh Bumma; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Myeloma
Interventions: Arlocabtagene Autoleucel; Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more

Conditions: Early Alzheimer's Disease
Interventions: Lecanemab IV, Placebo, Lecanemab SC; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 112
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 54
States / cities: Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 40 more

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide, Pirtobrutinib; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • California City, California • Duarte, California + 18 more

Conditions: Fetal Weight, Pregnancy, Machine Learning, Pregnancy - Prenatal Testing
Interventions: AI ultrasound diagnostic tool for fetal weight estimation; Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: New Orleans, Louisiana • Chapel Hill, North Carolina • Columbus, Ohio

About this Ohio State University Wexner Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Ohio State University Wexner Medical Center

Filter and sort this campus

Live official records

The HYALEX Pivotal Study

Lead-212 PSV359 Therapy for Patients With Solid Tumors

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Prospective Evaluation of an AI Diagnostic Ultrasound Tool for Fetal Weight Estimation

About this Ohio State University Wexner Medical Center institution page